Pembrolizumab with or without another drug for lung cancer after surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding a new drug (sacituzumab tirumotecan) to pembrolizumab for people with non-small cell lung cancer that did not completely disappear after initial treatment and surgery. The goal is to see if the combination works better than pembrolizumab alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-small cell lung cancer (NSCLC) that is stage II, IIIA, or IIIB (with lymph node involvement).
- Your cancer can be removed with surgery, and you are able to go through chemotherapy plus pembrolizumab before surgery.
- After surgery, your cancer did not completely go away (no pathological complete response).
- You have not had previous treatment for your current lung cancer (like chemotherapy or radiation) before this trial.
- You do not have certain rare types of lung tumors (like those in the superior sulcus or small cell).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the combination of pembrolizumab (Keytruda) with or without a new drug, sacituzumab tirumotecan (Sac-TMT), as initial treatment for advanced squamous non-small cell lung cancer. It aims to see if adding Sac-TMT after initial treatment helps keep cancer under control longer.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
This trial tests whether combining pembrolizumab (an immune treatment) with a lung ablation procedure can be safer and more effective for advanced non-small cell lung cancer after standard first treatment fails or the cancer comes back. It may help shrink tumors and improve control of the disease.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This trial tests whether adding pembrolizumab (an immune therapy) to standard chemotherapy helps people with certain non-squamous lung cancers that doctors think might be surgically removed. You might be considered if your planned treatment involves a “double platinum” chemotherapy or crizotinib and your cancer is potentially resectable.
This trial tests a combination of SYS6010 and an immunotherapy drug (anti-PD-(L)-1) given after surgery to prevent non-small cell lung cancer from coming back. It's for people whose cancer was removed but didn't shrink much with prior treatment before surgery.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.